M.R. García Campelo

机构：Universidade da Coruña, Complexo Hospitalario Universitario A Coruña, Instituto de Investigación Biomédica de A Coruña

发表论文 91 篇 · 总被引 4762 次 · h-index 15

代表论文

• SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer (2023 · Annals of Oncology · 被引 102)
• Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non–Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without Amivantamab (2025 · Journal of Clinical Oncology · 被引 17)
• Durvalumab after radiotherapy in patients with unresectable stage III non-small-cell lung cancer ineligible for chemotherapy: the DUART phase II nonrandomized controlled study (2025 · ESMO Open · 被引 9)
• MA12.07 Amivantamab Plus Lazertinib vs Osimertinib in First-Line, EGFR-Mutant Advanced NSCLC: Patient-relevant Outcomes from MARIPOSA (2024 · Journal of Thoracic Oncology · 被引 9)
• 66MO Durvalumab after radiotherapy (RT) in patients (pts) with unresectable stage III NSCLC ineligible for chemotherapy (CT): Final analysis of the phase II DUART study (2024 · Immuno-Oncology Technology · 被引 4)
• 5MO Effect of amivantamab dose interruptions on efficacy and safety of first-line amivantamab plus lazertinib in EGFR-mutant advanced NSCLC: Exploratory analyses from the MARIPOSA study (2024 · ESMO Open · 被引 4)